Will quantum computers revolutionize drug discovery?
Not yet, and "revolutionize" oversells it. As of August 2026, real quantum hardware has simulated only molecules of a few atoms — calculations any laptop does exactly in milliseconds — while genuinely useful chemistry needs fault-tolerant machines that exist only on vendor roadmaps. Even then, quantum computers would accelerate one step (electronic-structure calculation for hard molecules) in a pipeline whose bottlenecks are mostly elsewhere.
Yes in principle — costed since 2017 Quantum phase estimation can in principle compute ground-state energies of strongly correlated molecules to chemical accuracy, a task that defeats classical methods for some systems. Reiher and colleagues produced the first serious resource estimate for a pharmaceutically interesting molecule. It is a costed theory, not a demonstration: the machine it requires does not exist.
Yes — for molecules of a few atoms only Variational quantum eigensolver (VQE) experiments have computed the ground-state energies of textbook molecules on real devices. These are engineering milestones: the same numbers come out of an exact classical calculation on a laptop in milliseconds. No molecule beyond classical reach has ever been simulated on quantum hardware.
Disputed — classical chemistry keeps moving the goalposts A Google–QSimulate–Boehringer Ingelheim study asked where the classical–quantum advantage boundary actually sits for a real drug-relevant enzyme. The honest finding: today's classical methods handle it, and the quantum crossover point keeps receding as classical algorithms improve. Whether pharma-relevant molecules that are classically hard but quantumly cheap exist in useful numbers is an open, contested question.
"Revolutionize the pipeline"? Disputed even by quantum researchers A 2024 Nature Physics perspective co-authored by quantum-industry researchers (Google, Boehringer Ingelheim, academia) lays out where quantum computers could plausibly help: specific electronic-structure subproblems such as metal centres and covalent inhibitors. Most of drug discovery — target identification, ADMET, formulation, clinical trials — is not electronic structure and gains nothing from a quantum computer.
Useful machines promised from ~2029 — treat as a claim IBM's fault-tolerance roadmap is the most concrete public plan, and its 2029 target still falls short of published drug-chemistry resource estimates unless algorithms improve further. Roadmap dates from every vendor have slipped before. Until logical qubits are demonstrated at scale, dates are claims, not capabilities.
What could a quantum computer actually do for drug discovery?
One specific thing: compute the electronic structure of molecules whose electrons are so strongly correlated that classical methods either fail or become unaffordable. For most drug-like molecules, classical methods (DFT, coupled cluster, DMRG) are already accurate enough. The interesting cases are a minority — transition-metal active sites, bond-breaking, some photochemistry.
The quantum algorithm for this is quantum phase estimation: encode the molecule's electrons into qubits, evolve under the molecular Hamiltonian, and read the ground-state energy out of the interference pattern between amplitudes. No "trying all configurations at once" — the machine's advantage comes from storing the exponentially large electronic wavefunction in polynomially many qubits and extracting one number, the energy, by interference.
Everything published so far says this needs error-corrected machines. The estimates for a single industrially interesting energy calculation sit around 10^9–10^10 fault-tolerant gate operations — see the assessments above and why error correction changes the arithmetic.
What can today's hardware do?
Molecules of a few atoms, with visible error bars. The state of the art on real devices is VQE-style calculations of H2, LiH, BeH2 and similarly sized systems — a handful of qubits, results that need error mitigation to match values a classical computer produces exactly and instantly.
Pharma companies do run quantum pilot projects, and papers occasionally report "quantum-enhanced" screening hits. Read those carefully: in every published case so far, the quantum processing unit handled a small subproblem that a classical method could have handled as well or better. That is learning-by-doing, not capability.
You can get a feel for the actual scale yourself: build a two-qubit VQE ansatz in the lab and compare it with what current QPUs offer.
What would have to change for the answer to change?
Three things, all of them, in order:
- Fault tolerance at scale. Hundreds of logical qubits sustaining billions of operations. Vendor roadmaps put this at 2029 and beyond; none has demonstrated it.
- The classical frontier holding still. It hasn't. Every time quantum resource estimates improve, classical methods (DMRG, machine-learned force fields, neural wavefunctions) improve too, and the cytochrome P450 study shows how far they already reach.
- A demonstrated win on a real molecule. One verified case of a quantum computer producing a chemically relevant number that the best classical method could not — that would change this page overnight. It has not happened.
If all three land, the realistic outcome is still "a powerful new tool for hard electronic-structure problems", not a revolutionized pipeline. Related: can quantum computers fold proteins?
Classifications follow the QPU137 editorial policy: every applied label carries a date, source, scale, and hardware, or it does not render. Found an error? Report it.